Refractory non-Hodgkin lymphoma

Responses to CAR T-cell therapy still strong after one year

<p class="article-intro">Sattva S. Neelapu, MD, The University of Texas MD Anderson Cancer Center, presents the long-term follow-up of ZUMA-1: a pivotal trial of axicabtagene ciloleucel (axi-cel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (NHL).</p> <hr /> <p class="article-content"><p><iframe src="https://player.vimeo.com/video/246954389" width="640" height="360" frameborder="0" allowfullscreen="allowfullscreen"></iframe></p></p>
Back to top